Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Allogeneic B-cell Transfer Post-SCT
NCT02007811Phase 2Unknown
- Sponsor
- FAU Erlangen-Nürnberg Medical Faculty
- Start
- Nov 2013
- Primary completion
- Dec 2015
- Modality
- Adoptive Cell Transfer
- Countries
- 1
01
Overview
A Phase 2 trial of allogeneic donor derived B-lymphocytes in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), chronic myeloid leukemia (CML), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), sponsored by FAU Erlangen-Nürnberg Medical Faculty. Status: unknown.
02
Drugs
allogeneic donor derived B-lymphocytes
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)chronic myeloid leukemia (CML)non-Hodgkin lymphoma (NHL)Hodgkin lymphoma (HL)
Beyond the preview
Go deeper on NCT02007811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02007811.